To evaluate the role of apolipoprotein B (ApoB) in cardiovascular risk assessment, particularly in relation to LDL cholesterol (LDL-C), emphasizing its significance in identifying at-risk individuals.
Key Findings:
Individuals with discordantly high ApoB had higher cardiovascular event rates compared to those with concordant levels, highlighting the need for targeted interventions.
Discordantly low ApoB groups exhibited lower event rates, suggesting a potential protective effect.
The risk associated with discordance was independent of absolute ApoB and LDL-C levels, indicating the unique value of ApoB measurement.
VLDL particle count was a significant mediator of cardiovascular risk in the discordantly high ApoB group, warranting further investigation.
Interpretation:
ApoB provides a more comprehensive assessment of cardiovascular risk than LDL-C, particularly when discordance is present, indicating the need for its consideration in clinical practice to improve patient outcomes.
Limitations:
The clinical utility of VLDL measurement remains uncertain due to cost and availability, which may hinder its implementation.
The study primarily focused on a specific population, which may limit generalizability to broader patient groups.
Conclusion:
ApoB measurement should be considered in clinical practice, especially for individuals with metabolic syndrome or discordant lipid profiles, as it may enhance cardiovascular risk evaluation across diverse populations.
